Commitments and Contingencies (Detail) (USD $)	1 Months Ended		3 Months Ended				6 Months Ended					1 Months Ended							1 Months Ended		3 Months Ended				3 Months Ended	6 Months Ended	1 Months Ended		1 Months Ended		12 Months Ended	1 Months Ended			3 Months Ended	12 Months Ended		1 Months Ended			3 Months Ended
	Jun. 30, 2013	Oct. 31, 2012	Jun. 30, 2013		Jul. 01, 2012		Jun. 30, 2013		Jul. 01, 2012		Nov. 30, 2012 Actions	Mar. 31, 2010 Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. [Member]	Jan. 31, 2011 Pfizer - Neurontin Product [Member] Actions	Dec. 31, 2009 Wyeth - Protonix [Member] Actions	Jun. 30, 2010 Mylan Pharmaceuticals Inc. [Member] Patents	May 31, 2012 Several Generic Manufacturers [Member] Patents	Aug. 31, 2011 Several Generic Manufacturers [Member] Patents	Mar. 31, 2009 Several Generic Manufacturers [Member] Patents	Feb. 28, 2013 Lupin Ltd and Lupin Pharmaceuticals, Inc. [Member] Patents	Jan. 31, 2011 Teva USA and Teva Pharmaceutical Industries, Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. [Member]	Jun. 30, 2013 Teva USA and Teva Pharmaceutical Industries, Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. [Member]	Mar. 31, 2010 Pfizer - Bapineuzumab [Member] test_cases	Dec. 31, 2002 Pfizer - Bapineuzumab [Member] test_cases	Aug. 31, 2011 Pfizer - Rebif [Member]	Mar. 31, 2013 Pending Litigation [Member] Hormone Replacement Therapy [Member]	Jun. 30, 2013 Pending Litigation [Member] Hormone Replacement Therapy [Member] Claim	Aug. 31, 2004 Pending Litigation [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jun. 30, 2013 Pending Litigation [Member] American Optical Corp subsidiary of Warner-Lambert [Member] Claim	Jan. 31, 2011 Pending Litigation [Member] Pfizer - Neurontin Product [Member]	Nov. 30, 2010 Pending Litigation [Member] Pfizer - Neurontin Product [Member]	Dec. 31, 2008 Pending Litigation [Member] IREF -Trade Secrets Action [Member]	Oct. 31, 2010 Pending Litigation [Member] Apotex Inc. and Apotex Corp., Mylan Pharmaceuticals Inc. and Mylan Inc. [Member]	Dec. 31, 2005 Pending Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Mar. 31, 2005 Pending Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Sep. 26, 2004 Pending Litigation [Member] March 2005 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Dec. 31, 2012 Pending Litigation [Member] Court settlement rejection and Pfizer motion to appeal [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Dec. 31, 2010 Pending Litigation [Member] Court settlement rejection and Pfizer motion to appeal [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jun. 30, 2012 Pending Litigation [Member] March 2011 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Jun. 30, 2011 Pending Litigation [Member] March 2011 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member]	Mar. 31, 2011 Pending Litigation [Member] March 2011 proposed settlement [Member] Quigley Co, Inc., a wholly owned subsidiary [Member] Claimant	Jun. 30, 2013 Due first half of two thousand thirteen [Member] Teva USA and Teva Pharmaceutical Industries, Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. [Member]	Jun. 30, 2013 Due October two thousand fourteen [Member] [Member] Teva USA and Teva Pharmaceutical Industries, Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. [Member]	Jun. 30, 2013 Due two thousand thirteen [Member] Teva USA and Teva Pharmaceutical Industries, Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. [Member]	Jun. 30, 2013 Takeda [Member]
Loss Contingencies [Line Items]
Period of Exclusivity												6 months							6 years	6 months
Litigation Settlement, Amount																					$ 2,150,000,000																				$ 800,000,000	$ 800,000,000	$ 550,000,000
Litigation settlement, Company's percentage of settlement proceeds			64.00%
Litigation settlement, Takeda's percentage of settlement proceeds																																												36.00%
Notice of appeal and related motion																																October 2010				October 2010
Number of patents															3	2	3	3	3
Number of other patents																		2
Number of Claims, Infringement of Formulation Process																			2
Product litigation charge, pre-tax			(12,000,000)	[1]	473,000,000	[1]	(95,000,000)	[1]	1,287,000,000	[1]																									369,000,000		1,300,000,000
Product litigation charge, after-tax																																			229,000,000		800,000,000
The minimum percentage of votes needed from claimants to approve the proposed bankruptcy reorganization plan																																		75.00%
Percentage of claimants that agreed to 2004 proposed settlement																																		80.00%
Gross settlement amount offered																																		430,000,000
Loss Contingency Claims Payment Amount For Qualified Claimants Second Payment																																								300,000,000
Loss Contingency Settled Payment Of Legal Costs Of Plaintiff																																								19,000,000
Loss Contingency Claims Payment Amount For Qualified Claimants First Payment																																	215,000,000						500,000,000
Number of Ad Hoc Committee claimants agreeing to the company's proposed settlement offer																																								40,000
Agreed upon amount of assets (cash and non-cash) to be contributed to a special purpose trust created to pay claimants, if Quigley's proposed reorganization plan is approved by the court																																						964,500,000
Insurance Settlement Gross Recovery							80,000,000																				405,000,000
Insurance settlement collection period																											10 years
Number of claims seeking damages																										10,000		66,500
Number of Multiple-Plaintiff Actions											3
Unresolved actions, years outstanding	5 years		5 years				5 years
Cumulative percentage of actions settled																									98.00%
Litigation settlement expense																										1,700,000,000
Estimated minimum cost to resolve outstanding actions																										25,000,000
Damages awarded by the court																													47,400,000	65,400,000	38,700,000
Evironmental civil penalty, Environmental Protection Agency	2,200,000
Treble damages amount awarded, under appeal																													142,100,000
Number of actions													4	2
Number of test cases																							6
Number of additional test cases																						3
Number of test cases with civil actions																							6
Contract extension agreement period																								24 months
Environmental complaint and penalty demand, environmental protection agency		$ 216,000

[1] In the first six months of 2013, primarily includes an $80 million insurance recovery related to a certain litigation matter. In the second quarter and first six months of 2012, primarily includes charges for hormone-replacement therapy litigation. The first six months of 2012 also includes a $450 million charge in connection with an agreement-in-principle to settle a lawsuit by Brigham Young University related to Celebrex (which was ultimately settled for that amount). For additional information, see Note 12. Commitments and Contingencies.